Fidelity Wise Origin Bitcoin Fund amends trust agreement to allow in-kind share transactions
In a separate transaction on December 1, 2024, Freeman disposed of 11,431 shares at $8.9732 per share to cover tax withholding obligations related to the vesting of restricted stock units. This sale was not discretionary and was mandated by the company's equity incentive plans. After these transactions, Freeman holds 236,950 shares of Health Catalyst (NASDAQ:HCAT) common stock. InvestingPro analysis indicates the company appears undervalued, with analysts forecasting profitability this year. Subscribers can access 8 additional ProTips and a comprehensive Pro Research Report for deeper insights into HCAT's financial health and growth prospects. InvestingPro analysis indicates the company appears undervalued, with analysts forecasting profitability this year. Subscribers can access 8 additional ProTips and a comprehensive Pro Research Report for deeper insights into HCAT's financial health and growth prospects.
In a separate transaction on December 1, 2024, Freeman disposed of 11,431 shares at $8.9732 per share to cover tax withholding obligations related to the vesting of restricted stock units. This sale was not discretionary and was mandated by the company's equity incentive plans. After these transactions, Freeman holds 236,950 shares of Health Catalyst common stock.
In other recent news, Health Catalyst has seen significant developments. Financial services firm, Piper Sandler, has raised the price target for Health Catalyst to $12, citing the company's anticipated year-over-year growth of approximately 50% in adjusted EBITDA for 2025. This positive outlook is also reflected in the company's recent third-quarter financial results for 2024, which indicated a profitable execution and a revenue mix shifting back towards software.
In addition to Piper Sandler, Stephens also raised the price target for Health Catalyst to $9, following the company's third-quarter performance. The company's recent financial results disclosed a positive profit and loss execution and a revenue mix increasingly shifting back towards software.
In the recent earnings conference call, Health Catalyst reported its financial outcomes for the third quarter of 2024 and provided insights into the company's performance and future outlook. The leadership team expressed a positive outlook for the company's growth trajectory, providing financial projections for the remainder of 2024 and the full year of 2025. These are the most recent developments for Health Catalyst, a leader in healthcare data and analytics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.